Literature DB >> 12720132

Malignant transformation in IgM monoclonal gammopathy of undetermined significance.

S Montoto1, M Rozman, L Rosiñol, E Nadal, E Giné, M Aymerich, A Ferrer, J Esteve, F Bosch, A López-Guillermo, J Bladé, E Montserrat.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a frequent disorder characterized by the presence of a small serum M-protein in individuals with no evidence of multiple myeloma (MM), Waldenstrom's macroglobulinemia (WM), or primary amyloidosis (AL). Although one fourth of these individuals will develop a malignant disease, there are no well-established predictors of outcome, particularly in the IgM type MGUS. Among 434 patients diagnosed with MGUS from 1970 to 2001 with a minimum follow-up of 1 year, 52 (27 men and 25 women; median age, 67 years) of IgM type were identified. After a median follow-up of 5 years, five patients (9.6%) have developed WM. The risk of transformation was 13.3% (95% confidence interval [CI], 0 to 27) and 27.7% (95% CI, 0.3 to 55.1) at 10 and 20 years, respectively. The variables significantly associated with transformation were the proportion of bone marrow plasma cells (BMPC) and the percentage of bone marrow lymphocytes (BML). No significant differences in the risk of transformation were found between IgM MGUS and the remaining MGUS types. Thus, in IgM MGUS the rate of transformation was similar to the risk observed in other MGUS types, the percentage of BMPC and BML being the features significantly associated with evolution into WM. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720132     DOI: 10.1053/sonc.2003.50067

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

Review 1.  Prevalence, clinical aspects, and natural history of IgM MGUS.

Authors:  Mary L McMaster; Ola Landgren
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

2.  Current therapies for neuromuscular manifestations of paraneoplastic syndromes.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.